Logo image of HCAT

HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HCAT - US42225T1079 - Common Stock

2.42 USD
+0.04 (+1.68%)
Last: 12/26/2025, 8:00:02 PM
2.4101 USD
-0.01 (-0.41%)
After Hours: 12/26/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, HCAT scores 2 out of 10 in our fundamental rating. HCAT was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of HCAT have multiple concerns. HCAT has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCAT was profitable.
HCAT had a negative operating cash flow in the past year.
In the past 5 years HCAT always reported negative net income.
In the past 5 years HCAT reported 4 times negative operating cash flow.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

HCAT has a Return On Assets (-18.33%) which is comparable to the rest of the industry.
HCAT has a Return On Equity (-32.42%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -18.33%
ROE -32.42%
ROIC N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

HCAT has a worse Gross Margin (47.49%) than 68.57% of its industry peers.
HCAT's Gross Margin has declined in the last couple of years.
HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCAT has been increased compared to 1 year ago.
HCAT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HCAT is higher compared to a year ago.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.20, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT's Altman-Z score of -2.20 is on the low side compared to the rest of the industry. HCAT is outperformed by 65.71% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that HCAT is not too dependend on debt financing.
HCAT has a worse Debt to Equity ratio (0.46) than 74.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -2.2
ROIC/WACCN/A
WACC7.34%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

HCAT has a Current Ratio of 1.88. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
HCAT has a worse Current ratio (1.88) than 60.00% of its industry peers.
A Quick Ratio of 1.88 indicates that HCAT should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.88, HCAT is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.88
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

HCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.31%.
The Revenue has been growing slightly by 4.64% in the past year.
The Revenue has been growing by 14.63% on average over the past years. This is quite good.
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%

3.2 Future

Based on estimates for the next years, HCAT will show a small growth in Earnings Per Share. The EPS will grow by 7.75% on average per year.
The Revenue is expected to grow by 1.17% on average over the next years.
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y21.21%
EPS Next 5Y7.75%
Revenue Next Year1.22%
Revenue Next 2Y-0.78%
Revenue Next 3Y0.39%
Revenue Next 5Y1.17%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 16.13 indicates a correct valuation of HCAT.
HCAT's Price/Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 88.57% of the companies in the same industry.
When comparing the Price/Earnings ratio of HCAT to the average of the S&P500 Index (26.57), we can say HCAT is valued slightly cheaper.
HCAT is valuated cheaply with a Price/Forward Earnings ratio of 6.57.
HCAT's Price/Forward Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 97.14% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.04. HCAT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.13
Fwd PE 6.57
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

HCAT's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 98.4
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

HCAT's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.66%
EPS Next 3Y21.21%

More info and screens

0

5. Dividend

5.1 Amount

HCAT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

HEALTH CATALYST INC

NASDAQ:HCAT (12/26/2025, 8:00:02 PM)

After market: 2.4101 -0.01 (-0.41%)

2.42

+0.04 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners79.37%
Inst Owner Change-0.98%
Ins Owners4.73%
Ins Owner Change8.56%
Market Cap171.17M
Revenue(TTM)316.06M
Net Income(TTM)-107.62M
Analysts73.33
Price Target4.02 (66.12%)
Short Float %8.93%
Short Ratio8.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-0.72%
Max EPS beat(2)15.68%
EPS beat(4)2
Avg EPS beat(4)89.55%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)5
Avg EPS beat(8)389.25%
EPS beat(12)9
Avg EPS beat(12)423.71%
EPS beat(16)13
Avg EPS beat(16)328.14%
Revenue beat(2)0
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-1.41%
Revenue beat(4)0
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-1.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.46%
Revenue beat(12)2
Avg Revenue beat(12)-1.03%
Revenue beat(16)5
Avg Revenue beat(16)-0.71%
PT rev (1m)0%
PT rev (3m)-13.42%
EPS NQ rev (1m)-10.33%
EPS NQ rev (3m)-15.57%
EPS NY rev (1m)-6.82%
EPS NY rev (3m)-6.82%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-1.23%
Valuation
Industry RankSector Rank
PE 16.13
Fwd PE 6.57
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB N/A
EV/EBITDA 98.4
EPS(TTM)0.15
EY6.2%
EPS(NY)0.37
Fwd EY15.21%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS4.47
BVpS4.69
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.98
Profitability
Industry RankSector Rank
ROA -18.33%
ROE -32.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.49%
FCFM N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 83.43
Cap/Depr 43.42%
Cap/Sales 6.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.88
Altman-Z -2.2
F-Score5
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y21.21%
EPS Next 5Y7.75%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%
Revenue Next Year1.22%
Revenue Next 2Y-0.78%
Revenue Next 3Y0.39%
Revenue Next 5Y1.17%
EBIT growth 1Y28.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.38%
EBIT Next 3Y42.06%
EBIT Next 5Y29.55%
FCF growth 1Y24.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A

HEALTH CATALYST INC / HCAT FAQ

What is the fundamental rating for HCAT stock?

ChartMill assigns a fundamental rating of 2 / 10 to HCAT.


What is the valuation status for HCAT stock?

ChartMill assigns a valuation rating of 5 / 10 to HEALTH CATALYST INC (HCAT). This can be considered as Fairly Valued.


Can you provide the profitability details for HEALTH CATALYST INC?

HEALTH CATALYST INC (HCAT) has a profitability rating of 1 / 10.


Can you provide the financial health for HCAT stock?

The financial health rating of HEALTH CATALYST INC (HCAT) is 1 / 10.